TLR9 and cancer: Recent studies by Xu et al. [136] have shown that PEG-rGO functionalized with neoantigens and CpG oligodeoxynucleotide (CpG ODN being a TLR-9 agonist) can act as cancer vaccines, enhancing vaccine delivery and stimulating strong CD8+ T cell responses.